The domestic pharmaceutical market is likely to see strong growth in the coming three years. The main reason for this is believed to be the launch of new medicines, especially GLP-1 based medicines. A report by Systematics Research said India’s domestic pharmaceutical sector could grow at a high single-digit rate in this period. According to the report, growth in India’s branded formulations market is expected to be accelerated by the increased use and launch of GLP-1 drugs. This is likely to provide special benefits to Indian pharma companies that have a strong presence in the domestic market. However, the report also indicates that earnings from the US generic drug business may remain stable in the near future for most companies. Despite this, demand from the domestic market, launch of new products and increasing share of chronic therapy segment may support the overall growth of Indian pharmaceutical companies.